Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMKX000189
- Development stage
- Phase 2
- Lead developer
- Jeyou Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JMKX000189 is an orally administered small molecule drug under development primarily for the treatment of moderately to severely active ulcerative colitis and systemic lupus erythematosus. It is being developed by Jemincare (Jiangxi Jemincare Group) and has reached Phase 3 clinical trials for ulcerative colitis in China and Phase 2 trials for systemic lupus erythematosus. The mechanism of action remains undisclosed or unknown in public sources, but it is not described as a novel mechanism. The drug is also being investigated for potential use in stroke, with IND approval reported in the United States[1][2][3][4].
Beyond the preview
Go deeper on JMKX000189.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMKX000189.